JP2021517454A5 - - Google Patents
Info
- Publication number
- JP2021517454A5 JP2021517454A5 JP2020541437A JP2020541437A JP2021517454A5 JP 2021517454 A5 JP2021517454 A5 JP 2021517454A5 JP 2020541437 A JP2020541437 A JP 2020541437A JP 2020541437 A JP2020541437 A JP 2020541437A JP 2021517454 A5 JP2021517454 A5 JP 2021517454A5
- Authority
- JP
- Japan
- Prior art keywords
- immune cells
- arginase
- cells
- immune
- activity
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153782 | 2018-01-28 | ||
| EP18153782.0 | 2018-01-28 | ||
| PCT/EP2019/051806 WO2019145453A1 (en) | 2018-01-28 | 2019-01-24 | Arginase suppression for cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517454A JP2021517454A (ja) | 2021-07-26 |
| JP2021517454A5 true JP2021517454A5 (https=) | 2022-02-24 |
| JPWO2019145453A5 JPWO2019145453A5 (https=) | 2022-02-24 |
Family
ID=61074351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541437A Pending JP2021517454A (ja) | 2018-01-28 | 2019-01-24 | 癌治療のためのアルギナーゼ抑制 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210177897A1 (https=) |
| EP (1) | EP3743510A1 (https=) |
| JP (1) | JP2021517454A (https=) |
| CN (1) | CN111902532A (https=) |
| AU (1) | AU2019211067A1 (https=) |
| CA (1) | CA3125797A1 (https=) |
| WO (1) | WO2019145453A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3774843B1 (en) | 2018-03-29 | 2022-05-25 | Molecure SA | Dipeptide piperidine derivatives |
| GB201912030D0 (en) * | 2019-08-21 | 2019-10-02 | Cancer Research Tech Ltd | Binding molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431080A1 (en) * | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| EP2010211A4 (en) | 2006-03-23 | 2010-06-09 | Univ Johns Hopkins | ARGINASE II: TARGET FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS |
| EP2083812B1 (en) | 2006-11-21 | 2017-04-05 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
| US9266908B2 (en) | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| US20140120136A1 (en) * | 2012-10-12 | 2014-05-01 | The Babraham Institute | Mir-155 enhancement of cd8+ t cell immunity |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| ES2897635T3 (es) | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| WO2016187459A1 (en) | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| MX2018005274A (es) | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. |
| EP3538111B1 (en) * | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
-
2019
- 2019-01-24 AU AU2019211067A patent/AU2019211067A1/en not_active Abandoned
- 2019-01-24 US US16/963,380 patent/US20210177897A1/en not_active Abandoned
- 2019-01-24 CA CA3125797A patent/CA3125797A1/en active Pending
- 2019-01-24 WO PCT/EP2019/051806 patent/WO2019145453A1/en not_active Ceased
- 2019-01-24 CN CN201980021913.2A patent/CN111902532A/zh active Pending
- 2019-01-24 EP EP19705288.9A patent/EP3743510A1/en not_active Withdrawn
- 2019-01-24 JP JP2020541437A patent/JP2021517454A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| Rui et al. | Cancer immunotherapies: advances and bottlenecks | |
| JP7755890B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| US20260055157A1 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| Khan et al. | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors | |
| US20210338729A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF | |
| JP2024008968A (ja) | 複数の抗原を標的とするｃｏｍｐｏｕｎｄキメラ抗原受容体（ｃＣＡＲ）の組成物およびその使用方法 | |
| US11173179B2 (en) | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof | |
| CN114761037A (zh) | 结合bcma和cd19的嵌合抗原受体及其用途 | |
| Iwamura et al. | siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions | |
| US20210069241A1 (en) | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression | |
| EP3490590A2 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| CN106574272A (zh) | 靶向多样的多种抗原的通用嵌合抗原受体表达性免疫细胞及其制造方法及其在癌症、感染和自身免疫病的治疗中的应用 | |
| Testa et al. | CAR-T cell therapy in B-cell acute lymphoblastic leukemia | |
| Hu et al. | Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer | |
| WO2022037562A1 (en) | Engineered immunoresponsive cells and uses thereof | |
| US20220241327A1 (en) | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof | |
| WO2021259237A1 (en) | GENETIC ENGINEERING OF γδ T CELLS FOR IMMUNOTHERAPY | |
| Yu et al. | Revolution of CAR engineering for next-generation immunotherapy in solid tumors | |
| Chen et al. | Natural killer cells: the next wave in cancer immunotherapy | |
| JP2021517454A5 (https=) | ||
| JP2025513626A (ja) | Ｃｉｉｔａ遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| JP2025518033A (ja) | 免疫細胞クリスパースクリーニングのための方法及び組成物 | |
| Cortes-Hernandez et al. | Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview |